Neocortical neurons cultured from mice with expanded CAG repeats in the huntingtin gene: Unaltered vulnerability to excitotoxins and other insults

Neuroscience

Volumn 120, Issue 3, 2003, Pages 617-625

  Snider, B J ^a   Moss, J L ^a   Revilla, F J ^a   Lee, C S ^a   Wheeler, V C ^b   Macdonald, M E ^b   Choi, D W ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoptosis; Huntington's disease; Oxidative stress; Polyglutamine; Proteasome

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DIZOCILPINE MALEATE; MENADIONE; N METHYL DEXTRO ASPARTIC ACID; PARAQUAT; POLYGLUTAMINE; PROTEASOME; STAUROSPORINE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EXON; GENE; GENE EXPRESSION; HUNTINGTIN GENE; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MOUSE; NERVE CELL CULTURE; NONHUMAN; NUCLEOTIDE REPEAT; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0042767651     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(03)00382-8     Document Type: Article

References (77)

1. Albers D.S., Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl. 59:2000;133-154.
2. Avenet P., Leonardon J., Besnard F., Graham D., Frost J., Depoortere H., Langer S.Z., Scatton B. Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. Eur J Pharmacol. 296:1996;209-213.
3. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
4. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
5. Bogdanov M.B., Ferrante R.J., Kuemmerle S., Klivenyi P., Beal M.F. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J Neurochem. 71:1998;2642-2644.
6. Bogdanov M.B., Andreassen O.A., Dedeoglu A., Ferrante R.J., Beal M.F. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem. 79:2001;1246-1249.
7. Browne S.E., Ferrante R.J., Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 9:1999;147-163.
8. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease selective vulnerability of the basal ganglia . Ann Neurol. 41:1997;646-653.
9. Bus J.S., Aust S.D., Gibson J.E. Superoxide- and singlet oxygen-catalyzed lipid peroxidation as a possible mechanism for paraquat (methyl viologen) toxicity. Biochem Biophys Res Commun. 58:1974;749-755.
10. Bus J.S., Aust S.D., Gibson J.E. Lipid peroxidation a possible mechanism for paraquat toxicity . Res Commun Chem Pathol Pharmacol. 11:1975;31-38.
11. Butterworth N.J., Williams L., Bullock J.Y., Love D.R., Faull R.L., Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience. 87:1998;49-53.
12. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., Levine M.S. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res. 66:2001;525-539.
13. Chai Y., Koppenhafer S.L., Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci. 19:1999;10338-10347.
14. Chai Y., Koppenhafer S.L., Shoesmith S.J., Perez M.K., Paulson H.L. Evidence for proteasome involvement in polyglutamine disease localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro . Hum Mol Genet. 8:1999;673-682.
15. Chen N., Luo T., Raymond L.A. Subtype-dependence of NMDA receptor channel open probability. J Neurosci. 19:1999;6844-6854.
16. Choi D.W. Ionic dependence of glutamate neurotoxicity. J Neurosci. 7:1987;369-379.
17. Chun W., Lesort M., Lee M., Johnson G.V. Mutant huntingtin aggregates do not sensitize cells to apoptotic stressors. FEBS Lett. 515:2002;61-65.
18. Cooper J.K., Schilling G., Peters M.F., Herring W.J., Sharp A.H., Kaminsky Z., Masone J., Khan F.A., Delanoy M., Borchelt D.R., Dawson V.L., Dawson T.M., Ross C.A. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet. 7:1998;783-790.
19. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
20. de la Monte S.M., Vonsattel J.P., Richardson E.P. Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol. 47:1988;516-525.
21. 2+ homeostasis. Arch Biochem Biophys. 235:1984;343-350.
22. Dragunow M., Faull R.L., Lawlor P., Beilharz E.J., Singleton K., Walker E.B., Mee E. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport. 6:1995;1053-1057.
23. Ferrante R.J., Kowall N.W., Cipolloni P.B., Storey E., Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease histopathologic and neurochemical characterization . Exp Neurol. 119:1993;46-71.
24. Fiskum G., Murphy A.N., Beal M.F. Mitochondria in neurodegeneration acute ischemia and chronic neurodegenerative diseases . J Cereb Blood Flow Metab. 19:1999;351-369.
25. Gallagher M.J., Huang H., Pritchett D.B., Lynch D.R. Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 271:1996;9603-9611.
26. Gottron F.J., Ying H.S., Choi D.W. Caspase inhibition selectively reduces the apoptotic component of oxygen-glucose deprivation-induced cortical neuronal cell death. Mol Cell Neurosci. 9:1997;159-169.
27. Gwag B.J., Koh J.Y., DeMaro J.A., Ying H.S., Jacquin M., Choi D.W. Slowly triggered excitotoxicity occurs by necrosis in cortical cultures. Neuroscience. 77:1997;393-401.
28. Hackam A.S., Singaraja R., Wellington C.L., Metzler M., McCutcheon K., Zhang T., Kalchman M., Hayden M.R. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol. 141:1998;1097-1105.
29. Halliday G.M., McRitchie D.A., Macdonald V., Double K.L., Trent R.J., McCusker E. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol. 154:1998;663-672.
30. Hansson O., Castilho R.F., Korhonen L., Lindholm D., Bates G.P., Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J Neurochem. 78:2001;694-703.
31. Hickey M.A., Morton A.J. Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J Neurochem. 75:2000;2163-2171.
32. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Lingaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23:1999;181-192.
33. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
34. Hwang J.Y., Kim Y.H., Ahn Y.H., Wie M.B., Koh J.Y. N-methyl-D-aspartate receptor blockade induces neuronal apoptosis in cortical culture. Exp Neurol. 159:1999;124-130.
35. Jana N.R., Zemskov E.A., Wang G., Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet. 10:2001;1049-1059.
36. Kim M., Lee H.S., LaForet G., McIntyre C., Martin E.J., Chang P., Kim T.W., Williams M., Reddy P.H., Tagle D., Boyce F.M., Won L., Heller A., Aronin N., DiFiglia M. Mutant huntingtin expression in clonal striatal cells dissociation of inclusion formation and neuronal survival by caspase inhibition . J Neurosci. 19:1999;964-973.
37. Kobayashi Y., Kume A., Li M., Doyu M., Hata M., Ohtsuka K., Sobue G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem. 275:2000;8772-8778.
38. Koh J.Y., Wie M.B., Gwag B.J., Sensi S.L., Canzoniero L.M., Demaro J., Csernansky C., Choi D.W. Staurosporine-induced neuronal apoptosis. Exp Neurol. 135:1995;153-159.
39. Koh J.-Y., Choi D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods. 20:1987;83-90.
40. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 352:1991;77-79.
41. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci. 21:2001;9112-9123.
42. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., Chesselet M.F. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res. 58:1999;515-532.
43. Li S.H., Cheng A.L., Li H., Li X.J. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. J Neurosci. 19:1999;5159-5172.
44. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
45. Mann D.M., Oliver R., Snowden J.S. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathol (Berl). 85:1993;553-559.
46. Morton A.J., Leavens W. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res Bull. 52:2000;51-59.
47. Namura S., Hirt L., Wheeler V.C., McGinnis K.M., Hilditch-Maguire P., Moskowitz M.A., MacDonald M.E., Persichetti F. The HD mutation does not alter neuronal death in the striatum of Hdh(Q92) knock-in mice after mild focal ischemia. Neurobiol Dis. 11:2002;147-154.
48. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 399:1999;263-267.
49. Paulson H.L. Protein fate in neurodegenerative proteinopathies polyglutamine diseases join the (mis)fold . Am J Hum Genet. 64:1999;339-345.
50. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci. 15:1995;3775-3787.
51. Priestley T., Laughton P., Myers J., Le Bourdelles B., Kerby J., Whiting P.J. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol Pharmacol. 48:1995;841-848.
52. Qiu J.H., Asai A., Chi S., Saito N., Hamada H., Kirino T. Proteasome inhibitors induce cytochrome c-caspase-3-like protease- mediated apoptosis in cultured cortical neurons. J Neurosci. 20:2000;259-265.
53. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W.O. Jr, Miller G., Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet. 20:1998;198-202.
54. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology. 58:2002;695-701.
55. Rose K., Choi D.W., Goldberg M.P. Cytotoxicity in murine neocortical cell culture. Tyson C., Frazier J. In vitro biological methods, Vol. 1A. 1993;46-60 Academic Press, San Diego, CA.
56. Sanchez I., Xu C.J., Juo P., Kakizaka A., Blenis J., Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron. 22:1999;623-633.
57. Sanchez Mejia R.O., Friedlander R.M. Caspases in Huntington's disease. Neuroscientist. 7:2001;480-489.
58. Sattler R., Charlton M.P., Hafner M., Tymianski M. Determination of the time course and extent of neurotoxicity at defined temperatures in cultured neurons using a modified multiwell plate fluorescence scanner. J Cereb Blood Flow Metab. 17:1997;455-463.
59. Schauwecker P.E., Steward O. Genetic determinants of susceptibility to excitotoxic cell death implications for gene targeting approaches . Proc Natl Acad Sci USA. 94:1997;4103-4108.
60. Schmitt I., Bachner D., Megow D., Henklein P., Hameister H., Epplen J.T., Riess O. Expression of the Huntington disease gene in rodents cloning the rat homologue and evidence for downregulation in non-neuronal tissues during development . Hum Mol Genet. 4:1995;1173-1182.
61. Schumacher J.M., Hantraye P., Brownell A.L., Riche D., Madras B.K., Davenport P.D., Maziere M., Elmaleh D.R., Brownell G.L., Isacson O. A primate model of Huntington's disease functional neural transplantation and CT-guided stereotactic procedures . Cell Transplant. 1:1992;313-322.
62. Sefton B.M., Beemon K., Hunter T. Comparison of the expression of the src gene of rous sarcoma virus in vitro and in vivo. J Virol. 28:1978;957-971.
63. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal Biochem. 150:1985;76-85.
64. Snider B.J., Tee L.Y., Canzoniero L.M., Babcock D.J., Choi D.W. NMDA antagonists exacerbate neuronal death caused by proteasome inhibition in cultured cortical and striatal neurons. Eur J Neurosci. 15:2002;419-428.
65. Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.G., Patel K., DeMartino G.N., Marcelli M., Weigel N.L., Mancini M.A. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet. 8:1999;731-741.
66. Sun Y., Savanenin A., Reddy P.H., Liu Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 276:2001;24713-24718.
67. Tellez-Nagel I., Johnson A.B., Terry R.D. Studies on brain biopsies of patients with Huntington's chorea. J Neuropathol Exp Neurol. 33:1974;308-332.
68. Thor H., Smith M.T., Hartzell P., Bellomo G., Jewell S.A., Orrenius S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes a study of the implications of oxidative stress in intact cells . J Biol Chem. 257:1982;12419-12425.
69. Trost L.C., Lemasters J.J. A cytotoxicity assay for tumor necrosis factor employing a multiwell fluorescence scanner. Anal Biochem. 220:1994;149-153.
70. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA. 97:2000;8093-8097.
71. Wellington C.L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A., Sharp A., Thornberry N., Nicholson D.W., Bredesen D.E., Hayden M.R. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem. 275:2000;19831-19838.
72. Wheeler V.C., Gutekunst C.A., Vrbanac V., Lebel L.A., Schilling G., Hersch S., Friedlander R.M., Gusella J.F., Vonsattel J.P., Borchelt D.R., MacDonald M.E. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet. 11:2002;633-640.
73. Wheeler V.C., Auerbach W., White J.K., Srinidhi J., Auerbach A., Ryan A., Duyao M.P., Vrbanac V., Weaver M., Gusella J.F., Joyner A.L., MacDonald M.E. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet. 8:1999;115-122.
74. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet. 9:2000;503-513.
75. Zeron M.M., Chen N., Moshaver A., Lee A.T., Wellington C.L., Hayden M.R., Raymond L.A. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci. 17:2001;41-53.
76. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 33:2002;849-860.
77. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 23:2000;217-247.